Article
Effectiveness of intracameral dexamethasone injection in immune reaction after penetrating and posterior lamellar keratoplasty
Search Medline for
Authors
Published: | August 28, 2017 |
---|
Outline
Text
Purpose: The aim of this observational study is to evaluate the effectiveness of an adjuvant intracameral corticosteroid injection (ICI) in cases of severe endothelial immune reaction (SEIR) (anterior chamber cells and flare, retrocorneal precipitates, Descemet's folds and corneal edema) after penetrating keratoplasty (PKP) and posterior lamellar keratoplasty (PLK).
Methods: In this retrospective study, 24 subjects treated between November 2011 to September 2014 were divided into two groups. The control group received topical and systemic steroid therapy while the study group received additionally ICI (400µg dexamethasone). Outcome measures included changes in best corrected visual acuity (BCVA), central corneal thickness (CCT, Pentacam), endothelial cell count (ECC) and intraocular pressure (IOP). The follow-up examinations were conducted after a period of 6 weeks and 3 months. Results were compared using the Wilcoxon signed-rank test.
Results: BCVA of the patients in the study group increased from logMAR 1.5 ± 0.77 at baseline to 0.99 ± 0.44 (p=0.009) at six weeks and to 0.78 ± 0.45 (p=0.017) at three months following the ICI. The CCT decreased from to 835 ± 211 µm at baseline to 609 ± 63 µm (p=0.005) after 3 months. ECC showed a significant reduction 12 weeks after treatment in both groups (p=0.012 in the control group and p=0.005 in the study group). This reflects a mean ECC loss of 17% and 19% due to the immune reaction in the control and study group respectively. A significant temporary increase in the IOP was documented only in the control group (p=0.005).
Conclusion: The ICI seems to be a safe adjuvant approach, which improves therapeutic efficacy of SEIR after keratoplasty.